Study of OSE-127 vs Placebo in Patients With Moderate to Severe Active Ulcerative Colitis

Phase 2 Completed NCT04882007

Condition	Ulcerative Colitis
Phase	Phase 2
Sponsor	OSE Immunotherapeutics
Status	Completed
Enrollment	136 participants
Interventions	OSE-127
Start date	Oct 2, 2020
Completion date	Apr 30, 2024
Results posted	Jun 23, 2026

Summary

This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group study in patients with moderate to severe active ulcerative colitis.

Change From Baseline in Modified Mayo Score (MMS) at Week 10

From Baseline to Week 10 · units on a scale

Lusvertikimab 850 mg	-2.41 units on a scale
Lusvertikimab 450 mg	-2.68 units on a scale
Placebo	-1.52 units on a scale

p-value	0.036
Least Square Mean Difference	-0.90 (95% CI -1.73–-0.06)

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Coliti — Janssen Research & Development, LLC
GI Permeability Change in Response to Aquamin® — James Varani
A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Seve — Hoffmann-La Roche
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerativ — Janssen Research & Development, LLC
A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Mode — Janssen Research & Development, LLC
Efficacy and Mechanism of Fecal Microbiota Transplantation of the Bai Ethnicity in the Tre — First Affiliated Hospital of Kunming Medical University

All trials

This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.

English 한국어 日本語中文 Русский